Biotech News

Fennec Pharmaceuticals Announces Investigator-Sponsored Study to Be Conducted by University of Arizona Cancer Center

Fennec Pharmaceuticals Inc. (FENC)Fennec Pharmaceuticals Inc.Company update

~ University of Arizona Cancer Center Initiating Study to Explore Use of PEDMARK ® in AYA & Adult Patients with Solid Tumors Receiving Cisplatin ~ ~ This New Study and Other Independent, Institution-Led Research Continues to Expand Real-World Validation of PEDMARK ® Across New Tumor Types and

Related news

Fennec Pharmaceuticals Inc.

Ototoxicity Prevention Company Fennec Pharmaceuticals commercializes PEDMARK, a sodium thiosulfate formulation designed to reduce permanent hearing loss caused by cisplatin chemotherapy. Pediatric Commercial Foundation PEDMARK is approved for pediatric patients with localized, non-metastatic solid tumors. Fennec supports adoption through...

Recent company news

Stock data

Close
11.29 USD
Market cap
346.68M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States